The Chase Group is proud to announce the completion of the Chief Medical Officer search with Akcea Therapeutics. The CMO will provide innovative and visionary leadership to develop clinical and medical strategy for a pipeline that has the potential to change the approach to treating cardiometabolic lipid disorders. To learn more about The Chase Group’s strength in securing senior leadership talent, contact us at chase@chasegroup.com.
The Chase Group completes CMO search with Akcea Therapeutics
The Chase Group is proud to announce the completion of the Chief Medical Officer search with Akcea Therapeutics. The CMO will provide innovative and visionary leadership to develop clinical and medical strategy for a pipeline that has the potential to change the approach to treating cardiometabolic lipid disorders. To learn more about The Chase Group’s strength in securing senior leadership talent, contact us at chase@chasegroup.com.- Categories: Pharmaceutical
Aeglea Biotherapeutics Secures Another Executive for their Clinical Development Leadership Team
To support their rapid growth and expanding portfolio of rare disease programs, Aeglea Biotherapeutics retained The Chase Group and successfully secured a new Global Program…
Eli Lilly Cyramza® Team Grows Through Continued Partnership with Chase
Utilizing their knowledge and years of experience recruiting in the life sciences industry, The Chase Group has successfully secured a new Global Senior Medical Advisor,…
A New Era Begins with Head of Pathology Placement at Genmab
Dr. Suzana Couto joins Genmab Pharmaceuticals as Head of Pathology, leading the pathology teams located in Utrecht, Netherlands, and Princeton, New Jersey. This international biotechnology…-
The Chase Group Makes Another Successful Placement at Eli Lilly
The Chase Group is pleased to continue our partnership with Eli Lilly in the successful placement of a new Senior Medical Advisor, Medical Affairs on… -
Aeglea BioTherapeutics Builds Rare Disease Clinical Development Team Through Partnership with The Chase Group, Inc.
Through our ongoing partnership, Aeglea Biotherapeutics has secured a Vice President, Clinical Development, Rare Disease. The new Vice President will play a crucial role in… -
Eli Lilly Welcomes New Vice President, Immuno-Oncology Global & US Medical Affairs
The Chase Group is pleased to announce the placement of the Vice President, Immuno-Oncology Global & US Medical Affairs for Eli Lilly. The successful candidate…